Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
Exercise / conversionCommon shares without par value | 81,709 | $48.90 | $3,995,570.10 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · nonDerivative · entry 2 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
Exercise / conversionCommon shares without par value | 41,229 | $47.00 | $1,937,763.00 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 22:06 UTC |
MANNING JOSEPH JSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 37,500 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-20-000866 · edgar.xml · derivative · entry 3 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common shares · 37,500 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 22:06 UTC |
MANNING JOSEPH JSenior Vice President
|
SaleCommon shares without par value | 37,500 | $89.58 | $3,359,411.25 |
DisclosureSEC source: 0001179110-20-000866 · edgar.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,534 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.52 to $89.65, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes shares acquired pursuant to a dividend reinvestment feature. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 22:06 UTC |
MANNING JOSEPH JSenior Vice President
|
Exercise / conversionCommon shares without par value | 37,500 | $38.40 | $1,440,000.00 |
DisclosureSEC source: 0001179110-20-000866 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:04 UTC |
PEDERSON MICHAEL JSenior Vice President
|
Tax withholdingCommon shares without par value | 7,182 | $86.80 | $623,397.60 |
DisclosureSEC source: 0001179110-20-000212 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,038 Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:04 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 90 | $86.86 | $7,817.40 |
DisclosureSEC source: 0001179110-20-000214 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,766 Underlying: Common shares · 90 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:06 UTC |
Stratton John GDirector
|
GrantStock Equivalent Units · Derivative | 362 | $86.86 | $31,443.32 |
DisclosureSEC source: 0001179110-20-000215 · edgar.xml · derivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,651 Underlying: Common shares · 362 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 23, 2019 Filed Dec 30, 2019 23:40 UTC |
WHITE MILES DDirector · Chairman and CEO
|
GiftCommon shares without par value | 298 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-013194 · edgar.xml · nonDerivative · entry 3 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,160,471 Read SEC document |
| December 13, 2019 Filed Dec 30, 2019 23:40 UTC |
WHITE MILES DDirector · Chairman and CEO
|
GiftCommon shares without par value | 12,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-013194 · edgar.xml · nonDerivative · entry 2 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,160,769 Read SEC document |
| December 12, 2019 Filed Dec 30, 2019 23:40 UTC |
WHITE MILES DDirector · Chairman and CEO
|
GiftCommon shares without par value | 507 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-013194 · edgar.xml · nonDerivative · entry 6 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Wife Disclosed balance after: 0 F2 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his wife. Read SEC document |
| December 12, 2019 Filed Dec 30, 2019 23:40 UTC |
WHITE MILES DDirector · Chairman and CEO
|
GiftCommon shares without par value | 507 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-013194 · edgar.xml · nonDerivative · entry 5 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Wife Disclosed balance after: 507 F2 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his wife. Read SEC document |
| December 12, 2019 Filed Dec 30, 2019 23:40 UTC |
WHITE MILES DDirector · Chairman and CEO
|
GiftCommon shares without par value | 1,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-013194 · edgar.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,173,151 Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 21:02 UTC |
WOODGRIFT RANDEL WILLIAMSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 16,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-19-011236 · edgar.xml · derivative · entry 5 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,333 Underlying: Common shares · 16,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 21:02 UTC |
WOODGRIFT RANDEL WILLIAMSenior Vice President
|
SaleCommon shares without par value | 5,000 | $80.60 | $403,000.00 |
DisclosureSEC source: 0001179110-19-011236 · edgar.xml · nonDerivative · entry 3 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,562 Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 21:02 UTC |
WOODGRIFT RANDEL WILLIAMSenior Vice President
|
SaleCommon shares without par value | 16,000 | $80.52 | $1,288,315.20 |
DisclosureSEC source: 0001179110-19-011236 · edgar.xml · nonDerivative · entry 2 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,562 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.41 to $80.70, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 21:02 UTC |
WOODGRIFT RANDEL WILLIAMSenior Vice President
|
Exercise / conversionCommon shares without par value | 16,000 | $38.40 | $614,400.00 |
DisclosureSEC source: 0001179110-19-011236 · edgar.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:07 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 94 | $83.67 | $7,864.98 |
DisclosureSEC source: 0001104659-19-052641 · a4.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,647 Underlying: Common shares · 94 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:12 UTC |
Stratton John GDirector
|
GrantStock Equivalent Units · Derivative | 376 | $83.67 | $31,459.92 |
DisclosureSEC source: 0001104659-19-052642 · a4.xml · derivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,273 Underlying: Common shares · 376 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:20 UTC |
MANNING JOSEPH JSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 47,226 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-19-010084 · edgar.xml · derivative · entry 3 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 47,226 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:20 UTC |
MANNING JOSEPH JSenior Vice President
|
SaleCommon shares without par value | 47,226 | $85.14 | $4,020,684.68 |
DisclosureSEC source: 0001179110-19-010084 · edgar.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,532 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.88 to $85.31, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Includes shares acquires pursuant to a dividend reinvestment feature. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:20 UTC |
MANNING JOSEPH JSenior Vice President
|
Exercise / conversionCommon shares without par value | 47,226 | $47.00 | $2,219,622.00 |
DisclosureSEC source: 0001179110-19-010084 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 23:11 UTC |
Funck, Jr. Robert E.Senior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-19-009489 · edgar.xml · derivative · entry 6 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 Underlying: Common shares · 40,000 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 23:11 UTC |
Funck, Jr. Robert E.Senior Vice President
|
Tax withholdingCommon shares without par value | 26,818 | $85.56 | $2,294,548.08 |
DisclosureSEC source: 0001179110-19-009489 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,173 Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 23:11 UTC |
Funck, Jr. Robert E.Senior Vice President
|
Exercise / conversionCommon shares without par value | 40,000 | $34.94 | $1,397,600.00 |
DisclosureSEC source: 0001179110-19-009489 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 23:12 UTC |
PEDERSON MICHAEL JSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 23,008 | $0.00 Strike: $50.72 | $0.00 |
DisclosureSEC source: 0001179110-19-009490 · edgar.xml · derivative · entry 4 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,016 Underlying: Common shares · 23,008 shares Expires 2027-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 23:12 UTC |
PEDERSON MICHAEL JSenior Vice President
|
GiftCommon shares without par value | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-009490 · edgar.xml · nonDerivative · entry 3 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,220 Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 23:12 UTC |
PEDERSON MICHAEL JSenior Vice President
|
SaleCommon shares without par value | 23,008 | $86.39 | $1,987,704.84 |
DisclosureSEC source: 0001179110-19-009490 · edgar.xml · nonDerivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,220 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.32 to $86.44, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 23:12 UTC |
PEDERSON MICHAEL JSenior Vice President
|
Exercise / conversionCommon shares without par value | 23,008 | $50.72 | $1,166,965.76 |
DisclosureSEC source: 0001179110-19-009490 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 21:05 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
Exercise / conversionOption (right to buy) · Derivative | 32,363 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001179110-19-009357 · edgar.xml · derivative · entry 6 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 32,363 shares Expires 2024-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 21:05 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
Exercise / conversionOption (right to buy) · Derivative | 11,400 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-19-009357 · edgar.xml · derivative · entry 5 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 11,400 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 21:05 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
SaleCommon shares without par value | 43,763 | $85.77 | $3,753,705.68 |
DisclosureSEC source: 0001179110-19-009357 · edgar.xml · nonDerivative · entry 3 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,381 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.50 to $86.21, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 21:05 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
Exercise / conversionCommon shares without par value | 32,363 | $39.12 | $1,266,040.56 |
DisclosureSEC source: 0001179110-19-009357 · edgar.xml · nonDerivative · entry 2 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 21:05 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
Exercise / conversionCommon shares without par value | 11,400 | $34.94 | $398,316.00 |
DisclosureSEC source: 0001179110-19-009357 · edgar.xml · nonDerivative · entry 1 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 21:15 UTC |
Moreland Mary KExecutive Vice President
|
GrantOption (right to buy) · Derivative | 60,912 | $0.00 Strike: $86.86 | $0.00 |
DisclosureSEC source: 0001179110-19-009136 · edgar.xml · derivative · entry 3 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,912 Underlying: Common shares · 60,912 shares Expires 2029-07-31 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,304 on August 1, 2020, 20,304 on August 1, 2021, and 20,304 on August 1, 2022. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 21:15 UTC |
Moreland Mary KExecutive Vice President
|
GrantCommon shares without par value | 8,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-009136 · edgar.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,028 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 21:01 UTC |
Blount Sally E.Director
|
SaleCommon shares without par value | 2,500 | $87.65 | $219,120.50 |
DisclosureSEC source: 0001104659-19-043751 · a4.xml · nonDerivative · entry 1 Blount Sally E. · CIK 0001537286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,266 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.3633 to $87.9102, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 26, 2019 Filed Jul 31, 2019 21:07 UTC |
BIRD ROGERSenior Vice President
|
GiftCommon shares without par value | 2,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-043011 · a4.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,947 Read SEC document |
| July 24, 2019 Filed Jul 25, 2019 22:48 UTC |
BRYNELSEN CHARLESSenior Vice President
|
Tax withholdingCommon shares without par value | 1,650 | $88.74 | $146,421.00 |
DisclosureSEC source: 0001179110-19-008828 · edgar.xml · nonDerivative · entry 1 BRYNELSEN CHARLES · CIK 0001712459 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,461 Read SEC document |
| July 24, 2019 Filed Jul 27, 2019 01:30 UTC |
WOODGRIFT RANDEL WILLIAMSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 65,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001104659-19-042123 · a4.xml · derivative · entry 4 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,333 Underlying: Common shares · 65,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 24, 2019 Filed Jul 27, 2019 01:30 UTC |
WOODGRIFT RANDEL WILLIAMSenior Vice President
|
SaleCommon shares without par value | 65,000 | $88.01 | $5,720,325.00 |
DisclosureSEC source: 0001104659-19-042123 · a4.xml · nonDerivative · entry 2 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,562 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.00 to $88.06, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 24, 2019 Filed Jul 27, 2019 01:30 UTC |
WOODGRIFT RANDEL WILLIAMSenior Vice President
|
Exercise / conversionCommon shares without par value | 65,000 | $38.40 | $2,496,000.00 |
DisclosureSEC source: 0001104659-19-042123 · a4.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2019 Filed Jul 23, 2019 22:33 UTC |
Wellisch Alejandro DSenior Vice President
|
Tax withholdingCommon shares without par value | 524 | $87.49 | $45,844.76 |
DisclosureSEC source: 0001179110-19-008772 · edgar.xml · nonDerivative · entry 2 Wellisch Alejandro D · CIK 0001717526 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,668 Read SEC document |
| July 21, 2019 Filed Jul 23, 2019 22:33 UTC |
Wellisch Alejandro DSenior Vice President
|
GrantCommon shares without par value | 1,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-008772 · edgar.xml · nonDerivative · entry 1 Wellisch Alejandro D · CIK 0001717526 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,192 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| July 21, 2019 Filed Jul 23, 2019 22:34 UTC |
Salvadori Daniel Gesua SiveExecutive Vice President
|
Tax withholdingCommon shares without par value | 1,060 | $87.49 | $92,739.40 |
DisclosureSEC source: 0001179110-19-008773 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,088 Read SEC document |
| July 21, 2019 Filed Jul 23, 2019 22:34 UTC |
PEDERSON MICHAEL JSenior Vice President
|
Tax withholdingCommon shares without par value | 2,437 | $87.49 | $213,213.13 |
DisclosureSEC source: 0001179110-19-008774 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,220 Read SEC document |
| June 30, 2019 Filed Jul 1, 2019 21:02 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 93 | $84.10 | $7,821.30 |
DisclosureSEC source: 0001179110-19-008246 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,524 Underlying: Common shares · 93 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2019 Filed Jul 1, 2019 21:02 UTC |
Stratton John GDirector
|
GrantStock Equivalent Units · Derivative | 374 | $84.10 | $31,453.40 |
DisclosureSEC source: 0001179110-19-008247 · edgar.xml · derivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,881 Underlying: Common shares · 374 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 26, 2019 Filed Jun 27, 2019 21:01 UTC |
Salvadori Daniel Gesua SiveExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 71,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-19-008174 · edgar.xml · derivative · entry 3 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,313 Underlying: Common shares · 71,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 26, 2019 Filed Jun 27, 2019 21:01 UTC |
Salvadori Daniel Gesua SiveExecutive Vice President
|
SaleCommon shares without par value | 71,000 | $84.00 | $5,964,007.10 |
DisclosureSEC source: 0001179110-19-008174 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,148 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.00 to $84.04, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.